$1.2 billion market! Haizheng losartan potassium tablets approved by FDA

On April 10, Zhejiang Haizheng Pharmaceutical Co., Ltd issued a notice that its holding subsidiary Haizheng Pharmaceutical (Hangzhou) Co., Ltd (hereinafter referred to as "Haizheng Hangzhou company") received a notice from the U.S Food and Drug Administration (hereinafter referred to as "the U.S FDA"), and Haizheng Hangzhou company applied to the U.S FDA for a brief application for new drugs of losartan potassium tablets (anda, U.S generic drugs) Application, which means that the applicant can produce and sell the product in the U.S market) has been approved Up to now, Haizheng has invested about 6.8 million yuan in the drug research and development project Basic information of the drug name of the drug: anda no of losartan potassium tablet: 204795 dosage form: tablet specification: 25mg, 50mg, 100mg application matters: anda applicant: Losartan Potassium tablet of Haizheng Pharmaceutical (Hangzhou) Co., Ltd is mainly applicable to the treatment of hypertension and type 2 diabetic nephropathy The original research drug, Cozaar, was developed by Merck The domestic and foreign manufacturers mainly include Zhejiang Huahai Pharmaceutical Co., Ltd., China Resources Shuanghe Pharmaceutical Co., Ltd., Beijing Shuangji Pharmaceutical Co., Ltd., etc According to statistics, the global sales volume of losartan potassium tablets (25mg, 50mg, 100mg) in 2017 was about 1541853700 US dollars, of which the sales volume in the U.S market was about 97848400 US dollars; the global sales volume in 2018 was about 14235003600 US dollars, of which the sales volume in the U.S market was about 115860900 US dollars (data source: IMS).